Cargando…

A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy

Vascular abnormalities in tumors have a major impact on the immune microenvironment in tumors. The consequences of abnormal vasculature include increased hypoxia, acidosis, high intra-tumoral fluid pressure, and angiogenesis. This introduces an immunosuppressive microenvironment that alters immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duru, Gizem, van Egmond, Marjolein, Heemskerk, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686513/ https://www.ncbi.nlm.nih.gov/pubmed/33262763 http://dx.doi.org/10.3389/fimmu.2020.584723

Ejemplares similares

IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
por: Breedveld, Annelot, et al.
Publicado: (2019)

Monoclonal antibody‐mediated killing of tumour cells by neutrophils
por: Heemskerk, Niels, et al.
Publicado: (2018)

Immunotherapies targeting tumor vasculature: challenges and opportunities
por: Dianat-Moghadam, Hassan, et al.
Publicado: (2023)

HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges
por: Lin, Aifen, et al.
Publicado: (2021)

T cell immunotherapy for cervical cancer: challenges and opportunities
por: Yu, Lingfeng, et al.
Publicado: (2023)

Behavioral factors to modulate immunotherapy efficacy in cancer
por: Jongerius, C., et al.
Publicado: (2022)

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019)

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy
por: Sachamitr, Patty, et al.
Publicado: (2014)

Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease
por: Bos, Amelie, et al.
Publicado: (2022)

Seeking Windows of Opportunity to Shape Lifelong Immune Health: A Network-Based Strategy to Predict and Prioritize Markers of Early Life Immune Modulation
por: van Bilsen, Jolanda H. M., et al.
Publicado: (2020)

Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect
por: Suek, Nathan, et al.
Publicado: (2019)

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
por: Dong, Yan, et al.
Publicado: (2021)

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
por: Wang, Zhan, et al.
Publicado: (2016)

Vascular Endothelium as a Target of Immune Response in Renal Transplant Rejection
por: Piotti, Giovanni, et al.
Publicado: (2014)

Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy
por: Song, Yuan, et al.
Publicado: (2022)

A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019
por: De Stefano, Ludovico, et al.
Publicado: (2020)

Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
por: Hu, Weilei, et al.
Publicado: (2019)

Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics
por: Abdallah, Florence, et al.
Publicado: (2021)

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019)

Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity
por: van Delft, Myrthe A. M., et al.
Publicado: (2023)

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
por: Rausch, Johanna, et al.
Publicado: (2023)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

Arginase in the Vascular Endothelium: Friend or Foe?
por: Lucas, Rudolf, et al.
Publicado: (2014)

Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer
por: Tesone, Amelia J., et al.
Publicado: (2013)

Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation
por: Gibot, Sébastien, et al.
Publicado: (2019)

Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
por: Li, Sai, et al.
Publicado: (2020)

Targeting Resident Memory T Cells for Cancer Immunotherapy
por: Blanc, Charlotte, et al.
Publicado: (2018)

Complement System: An Immunotherapy Target in Colorectal Cancer
por: Talaat, Iman M., et al.
Publicado: (2022)

Similarities in the Metabolic Reprogramming of Immune System and Endothelium
por: Tang, Chu-Yik, et al.
Publicado: (2017)

Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment
por: Viúdez-Pareja, Cristina, et al.
Publicado: (2023)

Window of Opportunity
Publicado: (1996)

Dickkopf-1: A Promising Target for Cancer Immunotherapy
por: Chu, Hang Yin, et al.
Publicado: (2021)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
por: Rangel Rivera, Guillermo O., et al.
Publicado: (2021)

Commentary: Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation
por: Sigalov, Alexander B.
Publicado: (2020)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
por: Harvey, Jerry B., et al.
Publicado: (2020)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
por: Mollica Poeta, Valeria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mha1kj3m060qedtj6jvcr4rhfd